CRINETICS PHARM (CRNX)
(Delayed Data from NSDQ)
$29.24 USD
+1.02 (3.61%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $29.22 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRNX 29.24 +1.02(3.61%)
Will CRNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Other News for CRNX
CRNX March 2026 Options Begin Trading
JonesTrading Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly
CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News
Crinetics announces new data from its program evaluating PALSONIFY